Beclometasone dipropionate/formoterol fumarate (Fostair®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000846
English
Authors' recommendations:
Beclometasone dipropionate/formoterol fumarate (Fostair®) is recommended as an option for use within NHS Wales for the symptomatic treatment of patients with chronic obstructive pulmonary disease, with a FEV1 < 50% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2364
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Metered Dose Inhalers
- Pulmonary Disease, Chronic Obstructive
- Ethanolamines
- Bronchodilator Agents
- Drug Therapy, Combination
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.